These clinical trials include CAR-NK cells targeting B-NHL (CD19, CD22), AML (anti-CD33, anti-CLL1, anti-NKG2D), CD7+ hemopathies (anti-CD7), multiple myeloma (anti-BCMA), epithelial ovarian cancer (anti-mesothelin), castration-resistant prostate cancer (anti-PSMA), pancreatic cancer (ROBO1 CAR NK), metastatic solid tumors (anti-5T4, anti-MUC1, anti-NKG2D), and glioblastoma (anti-HER2). This evidence concerns the gene CD22 and acute myeloid leukemia.